Key Points Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and kidneys. Despite a high stock price, Lilly's strong returns and cash-flow generation demonstrate it's worth paying up for. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand for ...